Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.

Solly F, Angelot-Delettre F, Ticchioni M, Geneviève F, Rambaud H, Baseggio L, Plesa A, Debliquis A, Garnache-Ottou F, Roggy A, Campos L, Aanei C, Rosenthal-Allieri A, Georget MT, Lachot S, Jacob MC, Robillard N, Wuilleme S, Andre-Kerneis E, Cornet E, Salaun V, Bennami H, Lhoumeau AC, Arnoulet C, Jacqmin H, Neyman N, Latger-Cannard V, Massin F, Lainey E, Le Garff-Tavernier M, Costopoulos M, Roussel M, Mayeur-Rousse C, Eischen A, Raggeneau V, Derrieux C, Maurer M, Asnafi V, Trinquand A, Brouzes C, Lhermitte L.

Cytometry A. 2019 Jul 31. doi: 10.1002/cyto.a.23844. [Epub ahead of print]

PMID:
31364809
2.

CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.

Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, Biichle S, Daguindau E, Garnache-Ottou F, Tabruyn S, Adotevi O, Deschamps M, Ferrand C.

Cancer Res. 2019 Feb 1;79(3):663-675. doi: 10.1158/0008-5472.CAN-18-1078. Epub 2018 Dec 4.

PMID:
30514753
3.

Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies.

Magne J, Jenvrin A, Chauchet A, Casasnovas O, Donzel A, Jego L, Aral B, Guy J, Nadal N, Vernerey D, Callier P, Garnache-Ottou F, Ferrand C.

Exp Hematol Oncol. 2018 Feb 20;7:5. doi: 10.1186/s40164-018-0097-6. eCollection 2018.

4.

A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XNTM analyzers in routine laboratory practice.

Schillinger F, Sourdeau E, Boubaya M, Baseggio L, Clauser S, Cornet E, Debord C, Defour JP, Dubois F, Eveillard M, Galoisy AC, Geay MO, Mullier F, Nivaggioni V, Soenen V, Morel P, Garnache-Ottou F, Ronez E, Bardet V, Deconinck E.

Scand J Clin Lab Invest. 2018 May;78(3):159-164. doi: 10.1080/00365513.2018.1423702. Epub 2018 Jan 8.

PMID:
29310473
5.

Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.

Philippe L, Ceroi A, Bôle-Richard E, Jenvrin A, Biichle S, Perrin S, Limat S, Bonnefoy F, Deconinck E, Saas P, Garnache-Ottou F, Angelot-Delettre F.

Haematologica. 2017 Nov;102(11):1861-1868. doi: 10.3324/haematol.2017.169326. Epub 2017 Aug 10.

6.

[Liver X receptors as targets in inflammatory or leukemic plasmacytoid dendritic cells].

Ceroi A, Masson D, Garnache-Ottou F, Saas P.

Med Sci (Paris). 2017 Mar;33(3):345-348. doi: 10.1051/medsci/20173303024. Epub 2017 Apr 3. French. No abstract available.

7.

Increased levels of circulating platelet-derived microparticles are associated with metastatic cutaneous melanoma.

Moreau J, Pelletier F, Biichle S, Mourey G, Puyraveau M, Badet N, Caubet M, Laresche C, Garnache-Ottou F, Saas P, Seilles E, Aubin F.

Exp Dermatol. 2017 Oct;26(10):961-963. doi: 10.1111/exd.13339. Epub 2017 May 9.

PMID:
28266752
8.

How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage.

Gamonet C, Mourey G, Aupet S, Biichle S, Petitjean R, Vidal C, Pugin A, Naegelen C, Tiberghien P, Morel P, Angelot-Delettre F, Seilles E, Saas P, Bardiaux L, Garnache-Ottou F.

Transfusion. 2017 Mar;57(3):504-516. doi: 10.1111/trf.13989. Epub 2017 Feb 5. Erratum in: Transfusion. 2017 Jun;57(6):1584.

PMID:
28164307
9.

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.

Ceroi A, Masson D, Roggy A, Roumier C, Chagué C, Gauthier T, Philippe L, Lamarthée B, Angelot-Delettre F, Bonnefoy F, Perruche S, Biichle S, Preudhomme C, Macintyre E, Lagrost L, Garnache-Ottou F, Saas P.

Blood. 2016 Dec 8;128(23):2694-2707. Epub 2016 Oct 4.

10.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

11.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

12.

Tips and tricks for flow cytometry-based analysis and counting of microparticles.

Poncelet P, Robert S, Bailly N, Garnache-Ottou F, Bouriche T, Devalet B, Segatchian JH, Saas P, Mullier F.

Transfus Apher Sci. 2015 Oct;53(2):110-26. doi: 10.1016/j.transci.2015.10.008. Epub 2015 Oct 27. Review.

PMID:
26603057
13.

A new method for evaluating the risk of transferring leukemic cells with transplanted cryopreserved ovarian tissue.

Zver T, Alvergnas-Vieille M, Garnache-Ottou F, Roux C, Amiot C.

J Assist Reprod Genet. 2015 Aug;32(8):1263-6. doi: 10.1007/s10815-015-0512-4. Epub 2015 Jul 3.

14.

Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Dartigeas C, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Apr 14;5:10. doi: 10.1186/s40164-016-0038-1. eCollection 2015.

15.

New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C.

Exp Hematol Oncol. 2016 Mar 1;5:7. doi: 10.1186/s40164-016-0036-3. eCollection 2015. Erratum in: Exp Hematol Oncol. 2015;5:10.

16.

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F.

Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7.

17.

Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.

Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C, Garnache-Ottou F, Jacob MC, Kuhlein E, Macintyre-Davi E, Plesa A, Robillard N, Tkaczuk J, Ifrah N, Dombret H, Béné MC, Baruchel A, Garand R; French Multicenter Study Groups for Pediatric and Adult ALL.

Cytometry B Clin Cytom. 2015 Jan;88(1):21-9. doi: 10.1002/cyto.b.21195. Epub 2014 Nov 1.

18.

Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.

Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C, Garnache-Ottou F, Jacob MC, Kuhlein E, Macintyre-Davi E, Plesa A, Robillard N, Tkaczuk J, Ifrah N, Dombret H, Béné MC, Baruchel A, Garand R; for the French Multicenter Study Groups for Pediatric and Adult ALL.

Cytometry B Clin Cytom. 2014 Oct 1. doi: 10.1002/cytob.21195. [Epub ahead of print]

19.

Effects of anti-TNF-α agents on circulating endothelial-derived and platelet-derived microparticles in psoriasis.

Pelletier F, Garnache-Ottou F, Biichlé S, Vivot A, Humbert P, Saas P, Seillès E, Aubin F.

Exp Dermatol. 2014 Dec;23(12):924-5. doi: 10.1111/exd.12551.

PMID:
25255926
20.

Minimal residual disease detection in cryopreserved ovarian tissue by multicolor flow cytometry in acute myeloid leukemia.

Zver T, Alvergnas-Vieille M, Garnache-Ottou F, Ferrand C, Roux C, Amiot C.

Haematologica. 2014 Dec;99(12):e249-52. doi: 10.3324/haematol.2014.113373. Epub 2014 Sep 19. No abstract available.

21.

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X; French Society of Haematology.

Ann Hematol. 2014 Dec;93(12):1977-83. doi: 10.1007/s00277-014-2140-y. Epub 2014 Jul 5.

22.

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E.

Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.

23.

Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients.

Garnache Ottou F, Chandesris MO, Lhermitte L, Callens C, Beldjord K, Garrido M, Bedin AS, Brouzes C, Villemant S, Rubio MT, Belanger C, Suarez F, Deau B, Lefrère F, Hermine O, Asnafi V, Varet B, Macintyre E.

Br J Haematol. 2014 Jul;166(1):50-9. doi: 10.1111/bjh.12839. Epub 2014 Mar 25.

PMID:
24661013
24.

Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma.

Laresche C, Pelletier F, Garnache-Ottou F, Lihoreau T, Biichlé S, Mourey G, Saas P, Humbert P, Seilles E, Aubin F.

J Invest Dermatol. 2014 Jan;134(1):176-182. doi: 10.1038/jid.2013.288. Epub 2013 Jun 28.

25.

Opposing Mcl-1, the GALIG proapoptotic gene is upregulated as neutrophils die and underexpressed in Acute Myeloid Leukemia cells.

Mollet L, Robinet P, Dubois M, Aurouet A, Normand T, Charpentier S, Sureau A, Grandclement C, Garnache-Ottou F, Deconinck E, Brulé F, Rohrlich PS, Legrand A.

Mol Immunol. 2013 Nov;56(1-2):123-8. doi: 10.1016/j.molimm.2013.04.012. Epub 2013 May 25.

PMID:
23711389
26.

Minimal residual disease detection of leukemic cells in ovarian cortex by eight-color flow cytometry.

Amiot C, Angelot-Delettre F, Zver T, Alvergnas-Vieille M, Saas P, Garnache-Ottou F, Roux C.

Hum Reprod. 2013 Aug;28(8):2157-67. doi: 10.1093/humrep/det126. Epub 2013 Apr 30.

PMID:
23633552
27.

Blastic plasmacytoid dendritic cell neoplasm.

Angelot-Delettre F, Garnache-Ottou F.

Blood. 2012 Oct 4;120(14):2784. No abstract available.

28.

Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.

Garand R, Beldjord K, Cavé H, Fossat C, Arnoux I, Asnafi V, Bertrand Y, Boulland ML, Brouzes C, Clappier E, Delabesse E, Fest T, Garnache-Ottou F, Huguet F, Jacob MC, Kuhlein E, Marty-Grès S, Plesa A, Robillard N, Roussel M, Tkaczuk J, Dombret H, Macintyre E, Ifrah N, Béné MC, Baruchel A.

Leukemia. 2013 Feb;27(2):370-6. doi: 10.1038/leu.2012.234. Epub 2012 Aug 16.

PMID:
23070018
29.

Phosphatidylserine-expressing cell by-products in transfusion: A pro-inflammatory or an anti-inflammatory effect?

Saas P, Angelot F, Bardiaux L, Seilles E, Garnache-Ottou F, Perruche S.

Transfus Clin Biol. 2012 Jun;19(3):90-7. doi: 10.1016/j.tracli.2012.02.002. Epub 2012 Jun 5. Review.

30.

Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis.

Angelot-Delettre F, Biichle S, Ferrand C, Seilles E, Gaugler B, Harrivel V, Rosenthal-Allieri MA, Deconinck E, Saas P, Garnache-Ottou F.

Cytometry A. 2012 Aug;81(8):718-24. doi: 10.1002/cyto.a.22072. Epub 2012 Jun 6.

31.

Correlation between platelet-derived microparticle enumeration by flow cytometry and phospholipid-dependent procoagulant activity in microparticles: the centrifugation step matters!

Stagnara J, Garnache Ottou F, Angelot F, Mourey G, Seilles E, Biichlé S, Saas P, Racadot E.

Thromb Haemost. 2012 Jun;107(6):1185-7. doi: 10.1160/TH11-07-0509. Epub 2012 Apr 4. No abstract available.

32.

Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation.

Ferrand C, Garnache-Ottou F, Collonge-Rame MA, Larosa F, Blanc M, Behar C, Giannoli C, Garnier F, Tiberghien P, Deconinck E, Rohrlich PS.

Eur J Haematol. 2012 Mar;88(3):269-72. doi: 10.1111/j.1600-0609.2011.01741.x. Epub 2012 Jan 10.

PMID:
22168404
33.

CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Solly F, Angelot F, Garand R, Ferrand C, Seillès E, Schillinger F, Decobecq A, Billot M, Larosa F, Plouvier E, Deconinck E, Legrand F, Saas P, Rohrlich PS, Garnache-Ottou F.

Cytometry A. 2012 Jan;81(1):17-24. doi: 10.1002/cyto.a.21162. Epub 2011 Nov 3.

34.

Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis.

Pelletier F, Garnache-Ottou F, Angelot F, Biichlé S, Vidal C, Humbert P, Saas P, Seillès E, Aubin F.

J Invest Dermatol. 2011 Jul;131(7):1573-6. doi: 10.1038/jid.2011.57. Epub 2011 Mar 17. No abstract available.

35.

Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.

Brion A, Legrand F, Larosa F, Schillinger F, Garnache-Ottou F, Helias P, Fontan J, Heczko M, Delaby P, Daguindau E, Vuillier J, Chauchet A, Deconinck E.

Invest New Drugs. 2012 Aug;30(4):1697-702. doi: 10.1007/s10637-011-9632-6. Epub 2011 Jan 13.

PMID:
21229289
36.

[The role of dendritic cells in auto-inflammation seen in psoriasis].

Pelletier F, Angelot F, Garnache-Ottou F, Humbert P, Seilles E, Aubin F.

Ann Dermatol Venereol. 2010 Feb;137(2):132-9. doi: 10.1016/j.annder.2010.01.003. Epub 2010 Feb 1. French. No abstract available.

PMID:
20171437
37.

[Endothelial microparticles, an alarm signal for the immune system?].

Angelot F, Seillès E, Saas P, Garnache-Ottou F.

Med Sci (Paris). 2010 Jan;26(1):31-3. doi: 10.1051/medsci/201026131. French. No abstract available.

38.

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.

Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Rémy-Martin JP, Callanan M, Traverse-Glehen A, GrandClément C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C.

Blood. 2010 Mar 25;115(12):2420-9. doi: 10.1182/blood-2009-06-229112. Epub 2010 Jan 20.

39.

Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases.

Angelot F, Seillès E, Biichlé S, Berda Y, Gaugler B, Plumas J, Chaperot L, Dignat-George F, Tiberghien P, Saas P, Garnache-Ottou F.

Haematologica. 2009 Nov;94(11):1502-12. doi: 10.3324/haematol.2009.010934. Epub 2009 Jul 31.

40.

Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.

Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC; GOELAMS and GEIL study.

Br J Haematol. 2009 Jun;145(5):624-36. doi: 10.1111/j.1365-2141.2009.07679.x. Epub 2009 Apr 8.

PMID:
19388928
41.

[Immune monitoring of kidney transplant recipients: can markers predictive of over-immunosuppression be identified?].

Saas P, Courivaud C, Bamoulid J, Garnache-Ottou F, Seilles E, Ducloux D.

Ann Pharm Fr. 2008 Mar;66(2):115-21. doi: 10.1016/j.pharma.2008.03.004. Epub 2008 Jun 4. Review. French.

PMID:
18570910
42.

Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?

Garnache-Ottou F, Feuillard J, Saas P.

Br J Haematol. 2007 Feb;136(4):539-48. Review.

PMID:
17367408
43.

Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.

Robillard N, Cavé H, Méchinaud F, Guidal C, Garnache-Ottou F, Rohrlich PS, Avet-Loiseau H, Garand R.

Haematologica. 2005 Nov;90(11):1516-23.

44.

Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells.

Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P.

Blood. 2005 Feb 1;105(3):1256-64. Epub 2004 Sep 23.

45.

Can tolerogenic dendritic cells help to modulate allo-immune responses in the setting of hematopoietic cell transplantation?

Fresnay S, Garnache-Ottou F, Plumas J, Seilles E, Tiberghien P, Saas P.

Transpl Immunol. 2003 Jul-Sep;11(3-4):259-66. Review.

PMID:
12967779

Supplemental Content

Loading ...
Support Center